GlassScriptPhysician profile
Eugenia E Chen
NPI 1285739730
$2,879.34
in general payments reported to CMS, 2019-2025
15 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $788 · 2023: $885 · 2024: $599 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.68 | 2021-2025 | |
| Gilead Sciences, INC. | $599.57 | 2022-2025 | Epclusa, Vemlidy |
| Regeneron Healthcare Solutions, INC. | $357.45 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $278.49 | 2022-2024 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.04 | 2022-2024 | Xifaxan |
| Madrigal Pharmaceuticals | $146.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $116.37 | 2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $115.29 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $109.55 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $91.88 | 2022-2023 | Entyvio |
| Lilly USA, LLC | $89.23 | 2024 | Omvoh |
| Genzyme Corporation | $88.59 | 2023-2024 | |
| Celgene Corporation | $33.32 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $21.46 | 2022 | |
| Pfizer INC. | $19.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenia Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.